摘要
目的:研究糖尿病肾移植患者环孢素A(CsA)的药动学。方法:32例肾移植患者(术前既有糖尿病史的16例)术后服用CsA达稳态后,于服药前、服药后1,2,3,4,6,8,12 h静脉取血,采用均相酶扩大免疫分析法(EMIT)测定CsA浓度,以BAPP3.0软件拟合药动学参数。结果:CsA在糖尿病肾移植患者中的消除半衰期(t1/2)和体内平均滞留时间(MRT)较非糖尿病肾移植患者显著性降低(P<0.01,P<0.05),达峰时间(tmax)显著延长(P<0.01)。达峰浓度(Cmax)分别为(1 556.7±656.9)mg.L-1和(1 409.6±478.7)mg.L-1(P<0.05),2组曲线下面积(AUC)差异无显著性。结论:糖尿病对肾移植患者术后CsA的吸收和消除过程具有一定的影响,但不影响其生物利用度。
OBJECTIVE To study the pharmacokinetics of cyclosporine A （CsA） in the diabetic renal transplant recipients. METHODS 32 renal transplant patients（among them were 16 diabetic renal transplant recipients）were administrated CsA after renal transplantation and until the blood concentration of CsA was steady, then the blood was obtained before and after admin- istration of CsA at 1,2,3,4,6,8,12 h, Blood samples were collected from the recipients at the given time points, which was assayed by enzyme multiplied immunoassay technique （EMIT） for determination of the concentration of CsA, and the pharmaco- kinetic parameters were analyzed by BAPP （3.0） . RESUETS The comparison between the pharmacokinetic parameters of re- nal transplant recipients and those of the diabetic renal transplant recipients showed that there was a marked reduction in elimi- nation half life time（t1,/2） and mean retention time （MRT） （P〈0. 01, P〈0. 05） ,markedly increases in peak time （tmax） （P〈2 0. 05）. Peak concentration （Cmax） was（1556. 7 ± 656. 9）mg· L^-1 and（l 409. 6 ± 478. 7）mg· L^-1 （P〈0. 05）, respectively. There was no significant difference in AUC. CONCLUSION Diabetes may have an influence on the absorption and evacuation of CsA , but have no influence on its bioavailability.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第22期1803-1805,共3页
Chinese Journal of Hospital Pharmacy
基金
江苏省医学科技发展基金(NO.P200953)
关键词
糖尿病
肾移植
环孢素A
药动学
diabete
transplantation
cyclosporine A
pharmacokinetics
